Challenges

Particles of Life

Networks of Thoughts

Enhancing Clinical Care

Predicting Sustainable Future

Smart Matter Design

Highlights

Highlights

Enhancing Clinical Care

Predicting response to immunotherapies

Immune-checkpoint blockade therapies have revolutionized the treatment of metastatic melanoma in recent years. However, these therapies do not provide a long-lasting response for many patients. Indeed, 50% of patients succumb to metastatic disease within five years of diagnosis, with responses to immunotherapies even varying between different metastases within a single patient. The tumor microenvironment, specifically immune cells within it, plays a pivotal role in shaping tumor progression. Despite this, we still lack biomarkers to guide therapy and predict response to specific immunotherapies.